[Cl:1][C:2]1[C:3]([OH:40])=[C:4]([S:9]([N:12]([CH2:26][C:27]2[CH:32]=[CH:31][C:30]([C:33]3[CH:38]=[CH:37][C:36]([F:39])=[CH:35][CH:34]=3)=[CH:29][CH:28]=2)[CH2:13][C:14]2[CH:19]=[CH:18][CH:17]=[C:16]([CH2:20][NH:21][CH2:22][CH:23]([CH3:25])[CH3:24])[CH:15]=2)(=[O:11])=[O:10])[CH:5]=[C:6]([Cl:8])[CH:7]=1.[Cl:41][C:42]1[C:47]([Cl:48])=[CH:46][CH:45]=[CH:44][C:43]=1[N:49]=[C:50]=[O:51]>C1COCC1>[Cl:1][C:2]1[C:3]([OH:40])=[C:4]([S:9]([N:12]([CH2:13][C:14]2[CH:19]=[CH:18][CH:17]=[C:16]([CH2:20][N:21]([CH2:22][CH:23]([CH3:25])[CH3:24])[C:50]([NH:49][C:43]3[CH:44]=[CH:45][CH:46]=[C:47]([Cl:48])[C:42]=3[Cl:41])=[O:51])[CH:15]=2)[CH2:26][C:27]2[CH:32]=[CH:31][C:30]([C:33]3[CH:34]=[CH:35][C:36]([F:39])=[CH:37][CH:38]=3)=[CH:29][CH:28]=2)(=[O:11])=[O:10])[CH:5]=[C:6]([Cl:8])[CH:7]=1To a solution of 3,5-dichloro-N-((4′-fluorobiphenyl-4-yl)methyl)-2-hydroxy-N-(3-((isobutyl amino)methyl)benzyl)benzene sulfonamide (Compound E of Example 184, 0.04 g, 0.0667 wool, 1.0 eq) in 25 mL of dry THF at 0° C. was added 2,3-dichlorophenyl isocyanate (0.012 g, 0.0667 mmol, 1.0 eq). The reaction mixture was stirred at ambient temperature for 15 min and concentrated. The residue was purified by preparative HPLC to afford the title compound (0.02 g, 40%). 1H NMR (400 MHz, DMSO-d6) δ 0.85-0.87 (d, 6H), 2.0 (m, 1H), 3.09-3.11 (d, 2H), 4.44-4.46 (m, 3H), 4.49 (s, 4H), 7.03-7.05 (d, 2H), 7.13-7.15 (d, 3H), 7.21-7.29 (m, 4H), 7.33-7.35 (m, 1H), 7.43-7.45 (d, 2H), 7.56-7.62 (m, 4H), 7.80 (s, 1H), 8.00 (s, 1H). MS (EP: 788.0 (M−H)−.